Adjuvant Pembrolizumab for Melanoma — Approval Imminent?

Share this post

Pembrolizumab is poised to join the ranks of ipilimumab and nivolumab as adjuvant therapy for patients with stage III melanoma, after showing a 43% reduction in risk for recurrence.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply